Gilead to buy oral IL-23 receptor peptide HCXT-2001 for $1.275 billion
The deal adds an orally delivered peptide antagonist to Gilead's inflammatory disease pipeline.
TR
By Tom Reyes · Markets Editor
Oct 23 13:05 ETSource: BioPharm International
The wire
- 01Gilead is acquiring HCXT-2001, an oral IL-23 receptor peptide, in a transaction valued at $1.275 billion, according to BioPharm International.
- 02The deal is another sizeable bet on orally bioavailable peptides, a format readers track as an alternative to injectable biologics in inflammatory disease.
- 03Further terms, development stage and timing were not detailed in the report.
From the source
Read at biopharminternational.comGilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
